Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a decline, ending the day at $439.62 which represents a decrease of $-0.11 or -0.03% from the prior close of $439.73. The stock opened at $438.73 and ...

Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

New Ulm Public School Board Chairman Steve Gag administered the oath of office to newly-elected school board member Sarah ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...